Diamond v. Chakrabarty

United States Supreme Court – 1980

“Anything under the sun made by man is patentable.”

SHORT DESCRIPTION

Diamond v. Chakrabarty is one of the most influential patent law decisions in history. The United States Supreme Court addressed a fundamental question: whether a genetically modified living organism could be patented. The judgment transformed biotechnology law by confirming that human-made biological innovations are eligible for patent protection. This case laid the legal foundation for the modern biotechnology and pharmaceutical industries.

FACTS OF THE CASE

Dr. Ananda Chakrabarty, a microbiologist, developed a genetically engineered bacterium capable of breaking down crude oil. This organism was designed to assist in cleaning oil spills, offering significant environmental benefits. Chakrabarty filed a patent application claiming the bacterium as a patentable invention.

The U.S. Patent Office rejected the application, arguing that living organisms were products of nature and therefore not patentable subject matter. The Commissioner of Patents, Diamond, maintained that patent law did not extend to living entities.

Chakrabarty challenged the rejection, ultimately bringing the dispute before the United States Supreme Court.

ISSUES INVOLVED

The central legal issue was whether a genetically modified microorganism constituted patentable subject matter under U.S. patent law. Specifically, the Court examined whether living organisms fell within the statutory categories of patentable inventions.

COURT’S FINDINGS AND OBSERVATIONS

The Supreme Court ruled in favour of Chakrabarty, holding that the bacterium was patentable. The Court reasoned that patent law protects human-made inventions, regardless of whether they are biological in nature. It emphasized that Chakrabarty’s bacterium was not a naturally occurring organism but a product of human ingenuity.

The Court famously declared that patentable subject matter includes “anything under the sun that is made by man.” This interpretation broadened the scope of patent eligibility and acknowledged the growing importance of biotechnology.

SUGGESTION / PRACTICAL TAKEAWAY

This judgment revolutionized intellectual property protection for biotechnology. It underscores that innovation involving biological materials, when resulting from human intervention, may qualify for patent protection. Companies operating in pharmaceuticals, genetic engineering, and life sciences must strategically protect their research outputs through patents.

JUDGMENT

Year: 1980

The United States Supreme Court held that genetically modified living organisms are patentable subject matter when they are the result of human ingenuity.